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Should gluten-free foods be available on prescription?
Prescriptions improve outcomes for people with coeliac disease, write Matthew Kurien and
colleagues, but James Cave lambasts a costly system that frustrates patients and doctors alike
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Yes—Matthew Kurien, Sarah Sleet, David
Sanders
The NHS is facing unprecedented financial and operational
pressures, with nearly two thirds of trusts in deficit.1 The UK’s
healthcare spend as a proportion of gross domestic product is
currently lower than that of its western European neighbours,
exacerbating these pressures.2 The government has placed the
onus of restoring financial balance with healthcare professionals
by demanding improvements in productivity, efficiency, and
rationing services.1
In this context prescription of gluten-free food might seem like
an easy target for clinical commissioning groups (CCGs) trying
to contain costs, but it unfairly discriminates against people
with coeliac disease. In 2015, England annual prescriptions
costs for gluten-free foods were £25.7m (€30m; $32m)—0.3%
of the total NHS prescribing budget.3 Currently, about 40% of
clinical commissioning groups are restricting or removing
gluten-free food prescriptions,4 but Scotland, Wales, and
Northern Ireland are not following suit.
Equality of access
A gluten-free diet is the only treatment for coeliac disease.
Lifelong adherence to the gluten-free diet improves quality of
life5 and reduces the risk of long term complications such as
osteoporosis, vitamin D deficiency, iron deficiency, and (rarely)
malignancy. Adhering to this diet is challenging and some
evidence suggests it may be improved by access to gluten-free
foods on prescription.6 Although gluten-free foods are available
in supermarkets, they are often not found in local convenience
or budget stores, disadvantaging poorer people and those with
limited mobility.7 Furthermore, research shows that the average
cost of gluten-free products is three to four times that of standard
equivalent products.7 The National Institute for Health and Care
Excellence’s quality standards for coeliac disease highlight the
role of prescriptions to ensure that a gluten-free diet is affordable
and accessible for all patients.8
Grotesque media distortions have portrayed the NHS as
subsidising gluten-free junk food,9 but general practitioners can
prescribe only staple foods approved by the Advisory Committee
on Borderline Substances as appropriate for the person’s age
and sex.
Are gluten-free substitutes necessary? Yes. Although more and
more clinical commissioning groups insist that patients can
simply switch to eating rice and potato alternatives, they fail to
tackle the nutritional deficiencies of such alternatives. An
isocalorific portion of rice contains 90% less iron and 82% less
calcium than bread.10
Pernicious to this debate about prescription policies is the
persistent comparisons drawn between coeliac disease and
diabetes. However, both clinical advice and the policy position
of the patient charity Diabetes UK is that people with diabetes
derive no benefit from specialist foods.11 It makes no sense for
clinical commissioners to argue that not providing non-beneficial
food to one patient group justifies the same policy for essential
food products for coeliac disease.
Alternative strategies to prescriptions, such as direct supply
schemes from community pharmacies, or voucher allowances,
may be a more efficient way of delivering NHS support.
However, restricting or removing prescriptions is the dominant
policy currently being implemented.
Costs of a quick win
Medical nihilism—that is, assuming medical intervention is
futile—affects the wellbeing of patients with coeliac disease.
Targeting gluten-free food prescriptions may reduce costs in
the short term but there will be long term costs in terms of
patient outcomes. Would clinical commissioning groups
consider this if the treatment for coeliac disease was an
immunosuppressive drug and not food?
There is no other example in the NHS of a disease that is having
its treatment costs cut by 50-100%. If commissioners are
prepared to mislead the public when consulting on gluten-free
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prescriptions, can we trust their evidence base for other
important changes in service provision? Coeliac disease is the
first condition to have such healthcare policy restrictions applied.
If they are implemented throughout the NHS in England it is
only a matter of time before other misunderstood diseases are
dealt with similarly.
No—James Cave
In the 1960s, when gluten-free food was first made available
through prescription, it made sense to provide bread and other
staples through the NHS to ensure the availability of supply for
people with coeliac disease. But not now.
In 2016, it is ludicrous for the NHS to be treating a food product
as a drug and to require GPs and pharmacists to behave as
grocers. The system is bureaucratic, inefficient, expensive, and
completely hopeless for people with coeliac disease and their
families.
Complicated and expensive
The provision of food has never been more convenient, with a
household typically visiting a supermarket each week and 25%
visiting two or three times in a week.12 Online shopping and
home delivery of food are increasingly popular. However, if
you or a member of your household has coeliac disease, in
addition to your supermarket shop, you must also organise the
supply of your gluten-free products. This will require you to
negotiate the complex rules imposed by the NHS governing
what can be prescribed and how often, which you and your GP
are likely to find stressful and confusing.
Once the prescribing rules have been navigated, your gluten-free
products must be ordered and the prerequisite time allowed for
the prescription to be generated. You may have to collect the
prescription from your doctor and take it to a pharmacy, or it
may be sent electronically to your nominated pharmacy. The
pharmacist will then order the products from the wholesaler and
await delivery. Invariably the order is in bulk, so (assuming it
has arrived as planned) you will have a month’s supply of bread,
pasta, and flour to store at home.
It’s a time consuming rigmarole and, for the NHS, a very
expensive one. Walk into Tesco today and buy a 535 g Genius
gluten-free brown sandwich loaf and it will cost you £2.70,13
and yet the NHS listed price for the same loaf is £3.73.14 The
NHS with all its buying power is spending £1 more per loaf
than the average Tesco customer. This is a scandal. And it goes
further. The NHS pays anything up to £6.73 for 500 g of pasta,
and yet 500 g of gluten-free pasta will cost just £1.20 at a
supermarket. The eight basic gluten-free staples advised for
people with coeliac disease are all cheaper from a supermarket
than the NHS price. In addition, all prescription items attract a
dispensing fee and sometimes out-of-pocket expenses, which
are charged on top.
Alternatives to prescribing
In 2015, 1.6 million gluten-free items were dispensed by
pharmacies in England (a fraction of the over one billion items
they dispensed).15 If we stopped prescribing gluten-free products
tomorrow GPs would be freed from the time consuming
bureaucracy16 and the NHS would stop being ripped off.
A national voucher scheme or a personalised health budget
could be provided to ensure that patients receive recompense
for the extra expense of gluten-free products. This could be
funded from the money saved by no longer paying for overpriced
NHS gluten-free food. In addition, the price of gluten-free food
might fall further once proper market forces were in play. Most
importantly, people with coeliac disease who currently struggle
with the logistics of a lifelong gluten-free diet and a cumbersome
and antiquated supply system, would have the convenience and
choice we all enjoy.17
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